5 research outputs found
Additional file 1: of Multidisciplinary care of obese children and adolescents for one year reduces ectopic fat content in liver and skeletal muscle
STROBE statement for observational studies. (DOC 85 kb
Baseline characteristics of 287 overweight/obese (cases) and 40 lean (controls) children and adolescents.
<p>Data are presented as medians (interquartile range) due to a non-normal distribution. BMI, body mass index; diaBP, diastolic blood pressure; EMCL, extramyocellular lipid content; HbA1c, glycosylated hemoglobin; HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; IMCL, intramyocellular lipid content; LDL, low density lipoprotein; LFC, liver fat content; MFC, muscle fat content; SAT, subcutaneous adipose tissue volume; SDS, standard deviation score; sysBP, systolic blood pressure; VAT, visceral adipose tissue volume.</p><p>Baseline characteristics of 287 overweight/obese (cases) and 40 lean (controls) children and adolescents.</p
The correlation between MFC and HbA1c.
<p>The correlation between proton magnetic resonance spectroscopy measured muscle fat content (MFC) and glycosylated hemoglobin (HbA1c) in the 287 overweight/obese children and adolescents: R<sup>2</sup> = 0.07, <i>p</i> = 0.04.</p
The correlation between LFC and HbA1c.
<p>The correlation between proton magnetic resonance spectroscopy measured liver fat content (LFC) and glycosylated hemoglobin (HbA1c) in the 287 overweight/obese children and adolescents: R<sup>2</sup> = 0.09, <i>p</i> = 0.004.</p
DataSheet1_Metabolic effects of alternate-day fasting in males with obesity with or without type 2 diabetes.DOCX
Alternate-day fasting induces oscillations in energy stores. We hypothesized that repeated oscillations increases insulin secretion and sensitivity, and improve metabolic health in patients with obesity with or without type 2 diabetes (T2DM). Twenty-three male patients fasted every other day for 30 h for 6 weeks. Experiments included resting energy expenditure, continuous glucose monitoring, intravenous glucose tolerance test, euglycemic hyperinsulinemic clamp, body composition, hepatic triglyceride content, muscle biopsies which were performed at baseline, during 3 weeks without allowed weight loss, and after additional 3 weeks with weight loss. Bodyweight decreased ∼1% and further ∼3% during weeks one to three and four to six, respectively (p Clinical Trial registration: (ClinicalTrials.gov), (ID NCT02420054).</p